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Dysfunction of the virus-specific T cells is a cardinal feature 
in chronic persistent viral infections such as one caused by 
hepatitis C virus (HCV). In chronic HCV infection, virus-spe-
cific dysfunctional CD8 T cells often overexpress various in-
hibitory receptors. Programmed cell death 1 (PD-1) was the 
first among these inhibitory receptors that were identified to 
be overexpressed in functionally impaired T cells. The roles of 
other inhibitory receptors such as cytotoxic T lympho-
cyte-associated antigen-4 (CTLA-4) and T cell immunoglob-
ulin and mucin domain-containing molecule 3 (Tim-3) have al-
so been demonstrated in T-cell dysfunctions that occur in 
chronic HCV patients. Blocking these inhibitory receptors in 
vitro restores the functions of HCV-specific CD8 T cells and 
allows enhanced proliferation, cytolytic activity and cytokine 
production. Therefore, the blockade of the inhibitory re-




Hepatitis  C  virus  (HCV)  is  a  positive-sense  single-stranded 
RNA virus of the genus Hepacivirus in the family Flaviviridae, 
and it infects 170 million people worldwide (1). About 10∼
60% of the patients clear HCV spontaneously during the acute 
phase of the infection (2), while the others develop chronic 
persistent HCV infection that eventually leads to liver cirrhosis 
and hepatocellular carcinoma (3). Spontaneous resolution of 
HCV infection correlates with robust and sustained responses 
of the virus-specific T cells as demonstrated in humans (4-6) 
and  in  chimpanzees  (7,8),  the  sole  animal  model  of  HCV 
infection. On the other hand, the progression towards chronic 
HCV  infection  is  associated  with  weak  and  transient  re-
sponses of the virus-specific T cells (4-8). Various dysfunc-
tions  of  the  HCV-specific  T  cells,  such  as  inefficient  pro-
liferation, cytolytic activity, and cytokine production, are com-
monly  observed  during  the  chronic  stage  of  HCV  infection 
(reviewed in 9,10). Impaired cellular immune responses have 
been  attributed  to  the  mutations  within  the  T-cell  epitopes 
(11-13),  a  deviated  differentiation  of  T  cells  (14)  and  sup-
pressive functions of the regulatory T cells (15). Dysfunctional 
T cells are also observed in other chronic persistent viral in-
fections  such  as  hepatitis  B  virus  (HBV),  human  im-
munodeficiency virus (HIV) in humans, and lymphocytic cho-
riomeningitis  virus  (LCMV)  infection  in  mice  (16).
  A  n o v e l  m e c h a n i s m  o f  T - c e l l  d y s f u n c t i o n  w a s  r e c e n t l y  
demonstrated in a murine model of chronic LCMV infection 
(17).  It  was  found  that  the  expression  of  programmed  cell 
death 1 (PD-1) was up-regulated on dysfunctional LCMV-spe-
cific CD8 T cells in mice (17). In vivo blockade of the inter-
action between PD-1 and its ligand, PD-L1, restored the func-
tions of LCMV-specific CD8 T cells and reduced the viral titer 
(17). This influential discovery led to extensive investigations 
of  the  role  of  PD-1  in  the  regulation  of  T  cells  in  human 
chronic viral infections (16). More recently, other inhibitory 
receptors such as cytotoxic T lymphocyte asoociated antigen 
4  ( C T L A - 4 )  a n d  T  c e l l  i m m u n o g l o b u l i n  a n d  m u c i n  d o m a i n  
containing molecule 3 (Tim-3) have also been studied as the 
factors  that  can  cause  T-cell  impairments  in  chronic  viral 
infections. In this review, the roles of various inhibitory re-
ceptors in T-cell dysfunction found in chronic HCV infection Inhibitory Receptors in HCV Infection
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are  summarized.
THE ROLE OF PD-1 IN HCV INFECTION
PD-1 is one of the inhibitory receptors which are expressed 
on the T cells. It has two known ligands, PD-L1 and PD-L2, 
which are members of B7 family. Upon binding to its ligands, 
PD-1  confers  inhibitory  signal  to  the  T  cells  by  recruiting 
SH2-containing  phosphatases, S H P - 1  a n d  S H P - 2 ,  t o  i t s  i m -
munoreceptor tyrosine-based switch motif (ITSM). Recruited 
phospatases  then  block  the  T-cell  receptor  (TCR)-mediated 
activatory  signal  at  proximal  site  (16). 
    The role of PD-1 in virus-specific T cells in chronic viral 
infections was first identified in a murine model of chronic 
LCMV infection (17). As in chronic LCMV infection, the ex-
pression of PD-1 is similarly upregulated on the virus-specific 
CD8  T  cells  in  chronic  HCV  infection,  and  HCV-specific 
PD-1
high T cells are functionally impaired (18-20). In addition, 
a blockade of PD-1/PD-L1 interaction restores T-cell functions 
such as proliferation, cytolytic activity and cytokine (IFN-γ 
and TNF-α) production (18-20). The PD-1
high dysfunctional 
CD8 T cells express low levels of CD127, a marker of memo-
ry precursors, and high levels of CD57, a T-cell senescence 
marker  (18,20).  PD-1
highCD127
low  HCV-specific  CD8  T  cells 
are  known  to  frequently  undergo  apoptosis  (21).  PD-1  ex-
pression is likely to be influenced by the location of HCV-spe-
cific CD8 T cells in vivo, since HCV-specific CD8 T cells in 
the  liver have  a tendency  to express  higher  levels  of PD-1 
than those found in the peripheral blood (22). In addition, 
PD-1/PD-L1  blockade  was  able  to  functionally  restore 
H C V - s p e c i f i c  C D 8  T  c e l l s  o r i g i n a t i n g  f r o m  t h e  p e r i p h e r a l  
blood,  but  not  those  found  in  the  liver  (22).  The  dissim-
ilarities among the virus-specific CD8 T cells found in differ-
ent in vivo compartments need to be considered in further 
studies.
  T h e  r o l e  o f  P D - 1  w a s  a l s o  s t u d i e d  i n  t h e  a c u t e  s t a g e  o f 
HCV infection. Specifically, the relationship between the PD-1 
expression and the outcome of the acute HCV infection was 
questioned.  Recent  studies  showed  that  the  progression  of 
acute HCV infection to the chronic stage is associated with 
a high level of PD-1 on HCV-specific CD8 T cells during the 
acute infection, and the clearance of HCV infection is asso-
ciated  with  lower  levels  of  PD-1  expression  (23,24). 
However, at least one other study reported that the high level 
of PD-1 during the acute HCV infection is irrespective of the 
outcome of HCV infection (25). In a chimpanzee model of 
acute  HCV  infection,  intrahepatic  levels  of  PD-1  were  de-
termined by prospective liver biopsy and real-time PCR, and 
high mRNA levels of PD-1 were found to be associated with 
the development of chronic HCV infection (26). Intriguingly, 
the PD-1 levels in HCV-specific CD8 T cells declined through 
the escaping mutation of cognate T-cell epitopes even in the 
chronic stage of HCV infection (23). This implies that the high 
PD-1 levels on virus-specific CD8 T cells are maintained by 
persistent  TCR  stimulation,  which  henceforth  explains  why 
high PD-1 expression is routinely observed in chronic persis-
tent  viral  infections.
    Very  recently,  PD-1  expression  was  studied  in  the  ex-
perimental  vaccine  trials  and  subsequent  HCV  challenge  in 
chimpanzees  (Shin  et  al.,  unpublished  data).  In  this  study, 
the phenotypes of HCV-specific CD8 T cells were analyzed 
in HCV-challenged chimpanzees, which were part of a pre-
viously published adenovirus/DNA-based HCV NS3-NS5 vac-
cine study (27). HCV-specific CD8 T cells from the vaccinated 
chimpanzees  displayed  lower  levels  of  PD-1  and  a  greater 
ability to secrete IFN-γ than those from the control group. 
Consistent  with  these  findings,  intrahepatic  mRNA  levels  of 
P D - 1  a n d  P D - L 1  w e r e  s i g n i f i c a n t l y  l o w e r  i n  t h e  v a c c i n a t e d  
chimpanzees  than  in  the  control  chimpanzees.  These  data 
showed that the low expressions of PD-1 and PD-L1 are char-
acteristic features of vaccine-induced resolution of acute HCV 
infection,  and  that  the  attenuation  of  the  PD-1/PD-L1  in-
hibitory pathway during vaccine-induced HCV clearance may 
enable HCV-specific CD8 T cells to have enhanced anti-viral 
functions.
THE ROLE OF CTLA-4 IN HCV INFECTION
    CTLA-4 is structurally homologous to CD28, an important 
T-cell costimulatory molecule, and its expression is upregu-
lated on the activated T cells (28). CTLA-4 exerts T-cell in-
hibitory functions through diverse mechanisms. CTLA-4 binds 
to  CD80  and  CD86,  thus  competitively  inhibiting  the  inter-
action between CD28 and B7 molecules. In addition, CTLA-4 
recruits phosphatases such as SHP-2 and blocks the signal ac-
tivated  by  TCR  ligation  (28). 
    Although  the  blockade  of  CTLA-4  did  not  result  in  a  re-
storation  of  the  T  cell  functions  in  chronic  LCMV  infection 
in the previous study (17), recent findings on CTLA-4’s role 
in chronic HCV infection showed promising results (22,29). 
The HCV-specific CD8 T cells found in the livers of chronic 
HCV  patients  did  not  only  overexpress  PD-1,  but  also Inhibitory Receptors in HCV Infection
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CTLA-4. Co-expression of PD-1 and CTLA-4 was observed in 
liver-infiltrating lymphocytes, but not in peripheral blood lym-
phocytes  (29),  suggesting  the  phenotypic  differences  of  vi-
rus-specific  CD8  T  cells  in  different  in  vivo  compartments. 
PD-1
＋CTLA-4
＋  HCV-specific  T  cells  were  profoundly  dys-
functional (22). The functions of PD-1
＋CTLA-4
＋ HCV-specific 
CD8  T  cells  could  be  restored  by  a  combined  blockade  of 
PD-1 and CTLA-4, but not by PD-1 blockade or CTLA-4 block-
ade alone (29). For the development of a novel therapeutic 
strategy to restore the functions of HCV-specific CD8 T cells, 
a combined blockade of multiple inhibitory receptors needs 
to be done in order to maximize the anti-viral functions of 
H C V - s p e c i f i c  C D 8  T  c e l l s .
THE ROLE OF Tim-3 IN HCV INFECTION
Tim-3 was originally discovered as a specific marker of Th1 
CD4 T cells (30). It has been known that interaction of Tim-3 
with its ligand, galectin-9, promotes the cell death of Th1 cells 
and  terminates  Th1  responses. 
    The role of Tim-3 in chronic viral infections was first identi-
fied in HIV infection (31). In HIV-infected patients, the fre-
quency of Tim-3
＋ CD8 T cells increased, and the Tim-3 levels 
on the T cells correlated positively with the viral titer and in-
versely with CD4 T cell count (31). The HIV-specific CD8 T 
cells that  overexpress Tim  3  were  found  to  be functionally 
impaired, and a blockade of Tim-3 restored the functions of 
H I V - s p e c i f i c  C D 8  T  c e l l s  ( 3 1 ) .
    After this finding, the role of Tim-3 has also been studied 
in  chronic  HCV  infection  (32).  Tim-3  is  over-expressed  on 
HCV-specific dysfunctional CD8 T cells, and Tim-3
＋ CD8 T 
cells  are  of  CD127
lowCD57
high,  phenotype  which  is  identical 
to  that  of  PD-1
＋ C D 8  T  c e l l s  i n  c h r o n i c  H C V  i n f e c t i o n  
(18,20). Tim-3
＋PD-1
＋ HCV-specific CD8 T cells were prefer-
entially enriched in the intrahepatic compartment over the pe-
ripheral blood. Importantly, a blockade of Tim-3 resulted in 
a  f u n c t i o n a l  r e s t o r a t i o n  o f  H C V - s p e c i f i c  C D 8  T  c e l l s ,  e v i -
denced  by  increased  proliferation  and  IFN-γ production 
(32). The role of Tim-3 was also studied in HCV/HIV co-in-
fection (33). Compared to HCV infection alone, the frequency 
of  Tim-3
＋PD-1
＋  HCV-specific  CD8  T  cells  was  higher  in 
HCV/HIV co-infection, and Tim-3/PD-1 co-expression corre-
lated with liver damage (33). Either a Tim-3 blockade or a 
PD-1 blockade alone was found to be sufficient in restoring 
the  functions  of  Tim-3
＋PD-1
＋  HCV-specific  CD8  T  cells. 
Interestingly, Tim-3
＋PD-1
＋ phenotype was more frequent in 
HCV-specific CD8 T cells than in HIV-specific CD8 T cells, 
implying the varying degrees of impairments in different virus 
s p e c i f i c  T  c e l l s .
THE ROLE OF OTHER INHIBITORY RECEPTORS IN 
HCV INFECTION
In order to discover the other possible molecules that can po-
tentially  downregulate  T-cell  functions  in  chronic  viral  in-
fections, microarray and gene expression profiling were per-
formed in a murine model of LCMV infection (34). Several 
candidate  molecules  have  been  identified,  including  PD-1, 
lymphocyte activation gene-3 (LAG-3), 2B4, CD160, CTLA-4, 
paired  immunoglobulin-like  receptor  B  (PIR-B)  and  GP49B 
(34). A subsequent study demonstrated the complicated ex-
pression patterns of the inhibitory molecules and showed that 
the  co-expression  of  multiple  inhibitory  molecules  is  asso-
ciated with the severity of the infection (35). Very recently, 
co-expression of PD-1, 2B4, CD160, killer cell lectin-like re-
ceptor G1 (KLRG1), LAG-3 and CTLA-4 on CD8 T cells was 
studied in chronic HCV infection (36). Co-expression of mul-
tiple inhibitory receptors was observed on HCV-specific CD8 
T  cells and was  associated with  low  levels of  CD127  (36).
CONCLUSION
Since the discovery of PD-1 as an inhibitory receptor asso-
ciated with T-cell dysfunction in chronic LCMV infection, the 
roles of various inhibitory receptors on virus-specific CD8 T 
cells  have  been  extensively  studied  in  human  chronic  viral 
infections such as HCV, HBV and HIV infections. As blocking 
the inhibitory receptors in vitro restored the functions of vi-
rus-specific T cells, the blockade has been considered as a 
novel  strategy  for  the  treatment  of  chronic  viral  infections 
(37).  A  recent  study  evaluated  the  in  vivo  blocking  effects 
of anti-PD-1 antibody in macaques infected with simian im-
munodeficiency virus (SIV) (38). The PD-1 blockade was able 
to  enhance  the  immune  responses  and  resulted  in  a  sig-
nificant reduction of viral load and prolonged survival of the 
infected  hosts  (38).
    However,  for  an  in  vivo  blockade  of  the  inhibitory  re-
ceptors to be used in an actual therapy, some possible side 
effects  must  be  considered.  One  study  found  that  the  in-
fection of PD-L1-/- mice with a chronic LCMV strain was le-
thal due to severe immunopathologic damage (17), implying 
the importance of PD-1/PD-L1 in the prevention of virus-in-Inhibitory Receptors in HCV Infection
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duced lethal immunopathology. In particular, liver damage is 
known to be mediated by T-cell responses in HCV infections, 
and hence T cell-mediated liver damage may be aggravated 
by blockades of inhibitory receptors, resulting in lethal hep-
atitis  (39).
    As  mentioned  before,  some  patients  recover  from  acute 
HCV infection and exhibit low level of inhibitory receptors, 
while the others enter the chronic stage of HCV infection that 
results in upregulation of inhibitory receptors and progressive 
loss of the T-cell functions. Thus, an important question that 
arises is the mechanism that influences the body’s  immune 
system  to  choose  between  those  two  directions  of  disease 
outcome during the acute HCV infection. Perhaps it could be 
based  on  the  patient’s  genetic  backgrounds,  environmental 
influences, or both. In any case, the potential possibility that 
the blockade of the inhibitory molecules early on during the 
acute HCV infection may prevent the disease from progress-
ing  toward  a  more  problematic  chronic  stage  should  be 
considered.
    The restoration of the patients’ own anti-viral immune func-
tions has been pursued as a possible therapy for chronic HCV 
infection, but all efforts have been unsuccessful to date. The 
recent advancements in the understandings of the roles of the 
inhibitory  receptors  in  T-cell  dysfunction  will  hopefully  aid 
greatly in the development of a highly effective therapy for 
HCV  infection.
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